Sorry, I don't understand your search. ×
Back to Search Start Over

Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16.

Authors :
John P Pierce
Tarik Benmarhnia
Ruifeng Chen
Martha White
David B Abrams
Bridget K Ambrose
Carlos Blanco
Nicolette Borek
Kelvin Choi
Blair Coleman
Wilson M Compton
K Michael Cummings
Cristine D Delnevo
Tara Elton-Marshall
Maciej L Goniewicz
Shannon Gravely
Geoffrey T Fong
Dorothy Hatsukami
James Henrie
Karin A Kasza
Sheila Kealey
Heather L Kimmel
Jean Limpert
Raymond S Niaura
Carolina Ramôa
Eva Sharma
Marushka L Silveira
Cassandra A Stanton
Michael B Steinberg
Ethel Taylor
Maansi Bansal-Travers
Dennis R Trinidad
Lisa D Gardner
Andrew Hyland
Samir Soneji
Karen Messer
Source :
PLoS ONE, Vol 15, Iss 9, p e0237938 (2020)
Publication Year :
2020
Publisher :
Public Library of Science (PLoS), 2020.

Abstract

BackgroundMore smokers report using e-cigarettes to help them quit than FDA-approved pharmacotherapy.ObjectiveTo assess the association of e-cigarettes with future abstinence from cigarette and tobacco use.DesignCohort study of US sample, with annual follow-up.ParticipantsUS adult (ages 18+) daily cigarette smokers identified at Wave 1 (W1; 2013-14) of the PATH Study, who reported a quit attempt before W2 and completed W3 (n = 2443).ExposuresUse of e-cigarettes, pharmacotherapy (including nicotine replacement therapy), or no product for last quit attempt (LQA), and current daily e-cigarette use at W2.AnalysisPropensity score matching (PSM) of groups using different methods to quit.Outcome measures12+ months abstinence at W3 from cigarettes and from all tobacco (including e-cigarettes). 30+ days abstinence at W3 was a secondary outcome.ResultsAmong daily smokers with an LQA, 23.5% used e-cigarettes, 19.3% used pharmacotherapy only (including NRT) and 57.2% used no product. Cigarette abstinence for 12+ months at W3 was ~10% in each group. Half of the cigarette abstainers in the e-cigarette group were using e-cigarettes at W3. Different methods to help quitting had statistically comparable 12+ month cigarette abstinence at W3 (e-cigarettes vs no product: Risk Difference (RD) = 0.01, 95% CI: -0.04 to 0.06; e-cigarettes vs pharmacotherapy: RD = 0.02, 95% CI:-0.04 to 0.09). Likewise, daily e-cigarette users at W2 did not show a cessation benefit over comparable no-e-cigarette users and this finding was robust to sensitivity analyses. Abstinence for 30+ days at W3 was also similar across products.LimitationsThe frequency of e-cigarette use during the LQA was not assessed, nor was it possible to assess continuous abstinence from the LQA.ConclusionAmong US daily smokers who quit cigarettes in 2014-15, use of e-cigarettes in that attempt compared to approved cessation aids or no products showed similar abstinence rates 1-2 years later.

Subjects

Subjects :
Medicine
Science

Details

Language :
English
ISSN :
19326203
Volume :
15
Issue :
9
Database :
Directory of Open Access Journals
Journal :
PLoS ONE
Publication Type :
Academic Journal
Accession number :
edsdoj.96bebcf6dec34f568533a215f6999d4d
Document Type :
article
Full Text :
https://doi.org/10.1371/journal.pone.0237938